Addus HomeCare (ADUS) delivered a clean, if narrow, third-quarter beat. Adjusted earnings of $1.83 per share topped the $1.78 consensus and edged past the $1.82 Earnings Whisper number, a 0.5% surprise. Earnings grew 17.3% year over year. Revenue rose 7.0% to $387.73 million but came in 0.2% shy of consensus. The pattern was familiar: mid-single-digit top-line growth converted into double-digit profit growth through operating leverage. The more important development, however, is what management said about the next several quarters. Core personal care volumes cooled. Organic growth in that segment is guided lower for early 2027. And the pending AccentCare deal, while strategically significant, will dilute margins.

The quality of the beat deserves some scrutiny. Gross margin was essentially flat at 32.1% versus 32.2% a year ago, so the expansion came below the gross-profit line. Adjusted G&A improved to 18.9% of revenue from 19.2% in Q2 and 19.6% in Q1, and adjusted EBITDA rose 13.5% to $51.2 million at a 13.2% margin, up from 12.5% a year earlier. Net interest expense also fell to $0.7 million from $2.6 million after aggressive debt paydown, which flattered the bottom line. On a GAAP basis, EPS rose to $1.54 from $1.24. Cash conversion was softer. Operating cash flow of $40.9 million trailed last year's $51.3 million, and receivables climbed to $160.9 million as DSOs rose to 39.3 days, with Illinois stretching to 48 days. Management expects that working-capital benefit to reverse in Q4.

Beneath the headline, personal care growth is leaning more on price than on volume. Revenue per billable hour rose to $26.67 from $25.40, supported by prior rate increases in Illinois, Texas and New Mexico, the latter adding roughly 4% in July. Volume was weaker:

• Same-store billable hours grew just 1.6%, below the 2% to 2.5% target and down from 2.2% in each of the first two quarters, on September softness in Texas and Illinois.
• Same-store census remained 0.4% below last year. The year-over-year census growth management had hoped to see in the second half has not materialized and is now framed as flat to slightly positive in Q4.

The clinical segments told a better story. Home health swung to 2.5% same-store revenue growth from -6.6% in Q1 and -2.8% in Q2, with admissions up 13.8%. Hospice average daily census reached 4,031 and topped 4,100 in October. Reported hospice organic growth did slow to 4.1% from 11.1% in Q2, although it was 8.8% excluding a prior-year price-concession benefit.

The forward story centers on AccentCare. Addus agreed to pay about $275 million for AccentCare's personal care division outside New York, which carries roughly $280 million in annualized revenue. That would expand Addus's revenue base by nearly 19% and add about 13,700 census across ten states. The HSR waiting period has expired, and closing is expected in Q1 2027. The balance sheet can absorb the deal comfortably, with bank debt down to $24.3 million from $124.3 million at the end of 2025 and $617.8 million of revolver availability. Management also signaled appetite for larger hospice and home health acquisitions as valuations moderate. The trade-off is explicit, though. AccentCare runs at a high-single-digit EBITDA margin, so management expects 2027 consolidated margins to slip below 2026's roughly 13% level. With no Illinois rate increase on the horizon, personal care same-store growth is expected to moderate to 3% to 5% in the first half of 2027 from the recent 6.5% to 6.9% pace. A delayed Indiana acquisition and Medicaid work requirements rolling out in 2027 add further friction.

That helps explain the disconnect in the market setup. Shares have climbed 15.3% since the open following the August report and sit nearly 19% above the 200-day moving average. Earnings Whispers trend readings are broadly positive across price, sequential growth and momentum. Investor sentiment, however, was already negative heading into the report and slipped further, from -0.40 to -0.52. That is a meaningful but not dramatic deterioration, suggesting investors grew more cautious even as the stock advanced. Entering the print with a sizable run behind it and a modest beat in hand, the stock gives bears legitimate ammunition in the volume slowdown and the 2027 margin step-down.

The bottom line is that Addus executed well on the metrics it controls. Margins expanded, cost leverage improved, debt is nearly gone, and the clinical segments are recovering. Management also secured a deal that meaningfully scales its personal care footprint. The central tension is that the core personal care engine is slowing just as the company commits to a larger, lower-margin version of that same business. Investors will need to see census turn positive and AccentCare integrate smoothly to justify a stock that has already moved well ahead of a slightly softer 2027 outlook.